Key result
Cancer patients develop CTEPH in only ~1% of cases following symptomatic pulmonary embolism.
Why the study?
Although cancer is associated with an increased risk of CTEPH, the incidence of CTEPH after pulmonary embolism in cancer patients is unknown.
What is the incidence of CTEPH-likely patients after pulmonary embolism in cancer patients?
Cohort (n=129)
No
What is the incidence of CTEPH-likely patients after pulmonary embolism in cancer patients?
The frequency of screening-detected CTEPH-likely cases is negligible (0.75%) in cancer patients following a pulmonary embolism.
May not warrant routine CTEPH screening post-PE in cancer patients; leaves open confirmation in larger prospective cohorts.
INTRODUCTION: Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe condition which should be screened in patient with persistent dyspnea after pulmonary embolism (PE). After PE, CTEPH incidence was estimated between 0.1 and 9.1% in overall patients. Although cancer is associated with an increased risk of CTEPH, CTEPH incidence is still unknown in cancer patients with PE. We aimed to estimate the frequency CTEPH-likely patients after PE, in cancer patients. MATERIALS: We individualized cancer patients of a monocentric prospective registry including consecutive patients with symptomatic PE. The primary outcome was the frequency of "CTEPH-likely" patients defined by the European Respiratory Society (ERS) guidelines (an accelerated tricuspid regurgitation more than 2.8m/s and at least 1-2 segmental or larger-sized defects, after more than 3 months of therapeutic anticoagulation). RESULTS: We included 129 cancer patients with PE. Colorectal cancer (19%), breast cancer (17%) and prostate cancer (15%) were the most frequent cancers. PE occurred after surgery or medical immobilization in 17% of patients, while 26% of patients had history of venous thromboembolism. During the follow-up, 2 patients (1.5%) had a clinical suspicion of CTEPH and only 1 patient with ovarian cancer (0.75% 95%CI [0.0%-2.2%]) was classified as "CTEPH-likely", 6 months after PE. CONCLUSION: The frequency of screening for CTEPH seems negligible in PE patients with cancer. Concomitant cancer may affect the clinical suspicion of CTEPH.
No takes yet. Share an insight, caveat, or question.
Catella-Chatron et al. (2019) conducted a cohort in Pulmonary embolism in cancer patients (n=129). Symptomatic pulmonary embolism in cancer patients was evaluated on Frequency of 'CTEPH-likely' patients defined by ERS guidelines (95% CI 0.0%-2.2%). Among cancer patients with symptomatic pulmonary embolism, the frequency of CTEPH-likely status at 6 months was 0.75% (95% CI 0.0%-2.2%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: